Symptoms and disease activity
Remission articles covering treatment goals, symptom control, healing, monitoring, relapse prevention, and IBD outcomes. Symptom context emphasizes flares, remission, daily disease activity, and patient-relevant warning signs.
33 articles
Updated treat-to-target recommendations affect how inflammation and symptoms are monitored and when treatments should be changed. Clear targets and timing help patients and clinicians make consistent, evidence-informed...
A blood biomarker that predicts anti-TNF response could help people with IBD and their clinicians choose the right biologic sooner, avoiding ineffective treatment. This study reports that lower baseline serum oncostatin...
Mid-stage data suggest a dual-targeting approach may improve endoscopic remission for people with moderate–severe Crohn's disease, including many who previously failed advanced therapies. If confirmed in larger trials,...
Fatigue affects a large share of people with IBD and often persists despite remission; understanding treatment options and the need for a broad care plan can help patients and clinicians set realistic goals and...
Deep remission is an emerging treatment target in Crohn’s disease that combines symptoms and objective measures. A meaningful proportion of patients in VIVID-1 achieved corticosteroid-free deep remission with mirikizumab...
Patients and clinicians considering long-term use of mirikizumab for Crohn's disease may find evidence here that quality of life and common symptoms (fatigue, abdominal pain, stool frequency) can remain improved out to...
This study follows people from diagnosis and shows that about half achieve clinically meaningful improvements in quality of life by 3 years, but many remain below general population norms.
The study identifies an epithelial cell death signature (necroptosis then apoptosis) that appears before major inflammation and which correlated with relapse over 24–36 months, suggesting a possible early biomarker to...
People with IBD often have sleep problems and ongoing inflammation; melatonin could help both sleep and clinical disease activity, which may improve quality of life. The review suggests potential benefit but is not...
Bowel urgency is a common, distressing symptom in ulcerative colitis that matters for quality of life. This analysis indicates vedolizumab may reduce urgency and that early improvement is linked to better clinical and...
Shortening ustekinumab dosing intervals raised drug levels and was associated with high rates of steroid-free clinical remission in this small prospective IBD cohort, offering a practical option for patients who lose...
The paper identifies subtype-specific changes in enteric glial cells and mast cell activity in microscopic colitis and shows some treatment-associated reductions after budesonide; that helps explain disease biology and...
Orofacial granulomatosis often co-occurs with Crohn's disease and appears linked to a distinct Crohn's phenotype and treatment needs. The findings suggest that advanced therapies can be effective for OFG-associated CD...
The study suggests that asymptomatic C. difficile colonization may not predict return of IBD activity in patients who are in remission, which could influence how clinicians interpret positive C. difficile tests in people...
Dietary patterns may help reduce symptoms and improve quality of life for many people with ulcerative colitis and could influence inflammatory biomarkers and the gut microbiome, offering a nonpharmacologic adjunct to...
Many people with IBD remain symptomatic even when tests show little or no inflammation; recognising these persistent symptoms as a separate treatment target could improve quality of life. This reframes care to address...
A controlled trial found low-dose naltrexone did not induce endoscopic or clinical remission in Crohn's disease, but it showed a possible benefit for reducing fatigue. Patients seeking symptom relief without...
Patients with IBD often have joint and skin comorbidities that drive symptoms and treatment choices.
A potential link between ultra-processed food intake and Crohn’s relapse could influence dietary conversations for people in remission, but the current evidence is weak and not definitive.
The review proposes a low-cost, non-immunosuppressive adjunctive strategy targeting the gut microbiome and luminal metabolism to help maintain remission in UC, an area of strong patient interest but limited clinical...
Achieving histologic or biochemical remission in addition to clinical and endoscopic remission was associated with substantially lower relapse risk in ulcerative colitis across multiple follow-up intervals, suggesting...
New phase IIb trial results suggest an anti‑TL1A antibody (duvakitug) produced measurable benefit in both Crohn’s disease and ulcerative colitis, which could lead to a new treatment option if later phase III trials...
GI infections—especially CMV—were common in this study and much more frequent in acute severe UC than in remission, suggesting testing for infections can change diagnosis and management during severe flares.
The study evaluates how well first-line 5-ASA therapy achieves modern treatment targets (endoscopic, histologic, and biomarker remission) in real-world UC patients who are clinically in remission. Patients and clinicians...
Some rare autoinflammatory disorders can look like IBD but need different diagnostic thinking. Recognizing systemic signs and checking serum zinc may lead to a correct diagnosis and targeted care.
The study suggests quality-of-life and patient-reported measures can reveal a subgroup of UC patients in clinical remission who nevertheless have higher relapse risk, which could help personalize monitoring and care.
This review pools available pediatric data showing ustekinumab can induce and maintain remission after anti‑TNF failure, offering a treatment option for children with refractory IBD. Results are most robust for Crohn’s...
This study describes how IBD presents and early outcomes in children at a tertiary center, noting high rates of inflammation, nutritional problems, and early flares. Findings may help families and clinicians understand...
The study suggests that being symptom-free doesn’t guarantee the gut’s microbiome, metabolome, or epithelial functions have returned to a healthy state. Diet—especially ultraprocessed-food intake—was linked to persistent...
Fatigue affects a large majority of pediatric IBD patients and is linked to worse quality of life even when disease is in remission, so it’s a common problem families and clinicians will likely encounter. Understanding...
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Remission. The original article is from msn.com.
Patients considering switching biologics or clinicians choosing a second‑line therapy may care because the study suggests ustekinumab had better long‑term persistence and improving remission rates compared with anti‑TNF...
The article reports regulatory approvals and clinical-trial results for Omvoh (mirikizumab), which could offer a new option for people with moderate–severe Crohn’s who still have disruptive symptoms like bowel urgency....
